First-line pembrolizumab every 3 weeks followed by second-line ipilimumab, and first-line nivolumab followed by second-line ipilimumab are cost-effective strategies in patients with advanced melanoma expressing wild-type BRAF.
First-line pembrolizumab every 3 weeks followed by second-line ipilimumab, and first-line nivolumab followed by second-line ipilimumab are cost-effective strategies in patients with advanced melanoma expressing wild-type BRAF. These were the findings of a study published in the Journal of Clinical Oncology.
Patients with advanced disease have a much poorer prognosis, with only a 17% 5-year survival rate. However, patients with a more localized disease witness a 98% 5-year survival rate. Multiple phase 3 clinical trials that have evaluated nivolumab, ipilimumab, and pembrolizumab have found that while outcomes improve, these treatments are associated with adverse events and are quite expensive—the average annual cost of treatment with each drug easily surpasses $100,000. This makes it much harder to make decisions on the sequence of treatments and the dosing schedule.
For their current analysis, the authors developed a Markov model to estimate lifetime costs and quality-adjusted life years (QALY) for treatment sequences with first-line nivolumab, ipilimumab, nivolumab plus ipilimumab, pembrolizumab every 2 weeks, and pembrolizumab every 3 weeks. Patient health states were defined for initial treatment, first and second progression, and death. Rates for drug discontinuation, frequency of adverse events, disease progression, and death, obtained from randomized phase 3 trials, were used to determine the likelihood of transition between states.
The model showed that pembrolizumab every 3 weeks followed by second-line ipilimumab was more effective and less costly than the standard-of-care dacarbazine. The second cost-effective treatment was first-line nivolumab followed by second-line ipilimumab or ipilimumab followed by nivolumab. The incremental cost-effectiveness ratio of nivolumab followed by ipilimumab was $90,871/QALY. First-line nivolumab plus ipilimumab, followed by carboplatin plus paclitaxel chemotherapy, produced an incremental cost effectiveness ratio of $198,867/QALY.
The authors wrote that the drug acquisition cost of first-line ipilimumab and the cost of managing immune-related adverse events were significant factors that influenced their model.
Reference
Kohn CG, Zeichner SB, Chen Q, Montero AJ, Goldstein DA, Flowers CR.
Cost-effectiveness of immune checkpoint inhibition in BRAF wild-type advanced melanoma [published online February 21, 2017]. J Clin Oncol. doi: 10.1200/JCO.2016.69.6336.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More